A brief symptom index for advanced renal cell carcinoma

Health and Quality of Life Outcomes

Volumn 4, Issue , 2006, Pages

  Eton, David T ^a,b   Cella, David ^a,b   Bacik, Jennifer ^c   Motzer, Robert J ^c  

^a Research and Education   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON; INTERLEUKIN 2; ISOTRETINOIN; ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER;

ADULT; ADVANCED CANCER; AGED; APPETITE DISORDER; ARTICLE; CANCER PATIENT; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; FATIGUE; FEMALE; HIGH RISK POPULATION; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; METASTASIS; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELIABILITY; STATISTICAL DISTRIBUTION; SYMPTOMATOLOGY; TREATMENT OUTCOME; VALIDITY; WEAKNESS; BIOASSAY; COMORBIDITY; IMMUNOTHERAPY; INSTRUMENTATION; KIDNEY TUMOR; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; SICKNESS IMPACT PROFILE; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III; COMORBIDITY; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMMUNOTHERAPY; KARNOFSKY PERFORMANCE STATUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 33750442519     PISSN: 14777525     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-4-68     Document Type: Article

References (15)

1. American Cancer Society: Cancer Facts & Figures 2006. Atlanta, GA, American Cancer Society; 2006.
2. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408-417.
3. Borden EC, Parkinson D: A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol 1998, 25:3-8.
4. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen SX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
5. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) [abstract 4501]:; New Orleans, LA. Volume 22. ASCO: 2004:381s.
6. Stadler WM: Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 2005, 104:2323-2333.
7. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI: Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
8. Bacik J, Mazumdar M, Fairclough DL, Murphy BA, Mariani T, Motzer RJ, Cella D: The Functional Assessment of Cancer Therapy-BRM (FACT-BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 2004, 13:137-154.
9. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M: Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000, 18:2972-2980.
10. Yost KJ, Eton DT: Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005, 28:172-191.
11. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic significance of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
12. Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, NJ, Erlbaum; 1988.
13. Center for Drug Evaluation and Research: Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville, MD, US Food and Drug Administration; 2006:1-32.
14. Eton DT, Yost KJ, Cella D: Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy. Clin Lung Cancer in press.
15. Rini BI, Sosman JA, Motzer RJ: Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Biology, clinical results and future development. BJU Int 2005, 96:286-290.